Injectables in the prostate

Current Opinion in Urology

Volumn 18, Issue 1, 2008, Pages 28-33

  Saemi, Arash M ^a   Plante, Mark K ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

BPH; Ethanol; Injection; Prostate

Indexed keywords

BOTULINUM TOXIN A;

DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; GOLD THERAPY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MORBIDITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION; UROLOGIC SURGERY;

BOTULINUM TOXIN TYPE A; ETHANOL; HUMANS; INJECTIONS, INTRALESIONAL; MALE; PROSTATIC HYPERPLASIA; UROLOGIC DISEASES;

EID: 37349095898     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3282f20169     Document Type: Review

References (27)

1. Chancellor MB, Yoshimura N. Voiding function and dysfunction. Physiology and pharmacology of the bladder and urethra. In: Walsh PC, Vaughan ED Jr, Wein AJ, et al., editors. Campbell's urology. Philadelphia: Saunders; 2002. pp. 829-1743.
2. Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 2004; 172:20-26.
3. Talwar G, Pande S. Injection treatment of enlarged prostate. Br J Surg 1966; 53:421-427.
4. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170:530-547.
5. Shipman JJ, Akilie AN. Treatment by prostatic injection of acute urinary retention due to prostatic hyperplasia. Br Med J 1967; 2:418-419.
6. Chuang YC, Chiang PH, Huang CC, et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66:775-779.
7. Chuang YC, Chiang PH, Yoshimura N, et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006; 98:1033-1037. Intraprostatic injection with botulinum toxin type A was reported to have encouraging and sustaining results for a group of 41 men with symptomatic BPH. Given the preliminary study, the authors provided hints of the design of future multicenter randomized trials.
8. Geurcini F, Giannantoni A, Bard R. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: a multicenter feasibility study [abstract]. J Urol 2005; (Suppl):376.
9. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62:259-264.
10. Park DS, Cho TW, Lee YK, et al. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006; 47:706-714. In the evaluation of 52 patients in a 3-month follow-up study, nitric oxide was suggested to have a role in the action mechanism of BONT-A in BPH.
11. Chiang P, Chuang Y, Huang C, et al. Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. Urology 2003; 61:797-801.
12. Savoca G, De Stefani S, Gattuccio I, et al. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report. European Urology 2001; 40:504-508.
13. Chuang Y-C, Chancellor MB. The application of botulinum toxin in the prostate. J Urol 2006; 176:2375-2382. This study investigated the mechanism of BONT-A on the rat prostate, shedding light on the possibility of the dual actions of the injectable on the static and dynamic components of BPH.
14. Chuang Y-C, Huang C-C, Kang H-Y, et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006; 175:1158-1163.
15. Kuo HC. Prostate botulinum A toxin injection: an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65:670-674.
16. Larson TR, Scottsdale AZ, Huidobro C, et al. Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIs for accurate changes in size of the prostate [abstract]. J Urol 2005; (Suppl):376.
17. Chuang YC, Tu CH, Huang CC, et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006; 6:12. This study investigated the effects of BONT-A on the canine prostate, as well as on eight men with BPH related bladder outlet obstruction. Encouraging results are reported for this injectable, as well as the interesting suggestion of apoptotic induction with BONT-A injection in the canine prostate.
18. Goya N, Ishikawa N, Ito F, et al. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol 1999; 162:383-386.
19. Plante MK, Gross AL, Kliment JJ, et al. Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU International 2003; 91:94-98.
20. Chuang YC, Chiang PH, Yoshimura N, et al. Efficacy and length of symptom improvement after botulinum toxin type A injection in BPH patients not correlated with change in prostate volume [abstract]. In: Abstracts of AUA 2007; 19-24 May 2007; Anaheim. Linthicum: American Urological Association; 2007. Abstract 1837.
21. Chuang YC, Giannantoni A, Chancellor MB. The potential and promise of using botulinum toxin in the prostate gland. BJU Int 2006; 98:28-32.
22. Mutaguchi K, Matsubara A, Kajiwara M, et al. Transurethral ethanol injection for prostatic obstruction: An excellent treatment strategy for persistent urinary retention. Urology 2006; 68:307-311. This describes the first study to investigate the efficiency of transurethral ethanol injection of the prostate (TUEIP) for patients with persistent urinary retention due to prostatic obstruction. Encouraging outcomes are reported in the group of 21 men evaluated over a period of 2-24 months.
23. Ditrolio J, Patel P, Watson RA, et al. Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol 2002; 167:2100-2104.
24. Plante MK, Bunnell ML, Trotter SJ, et al. Transurethral prostatic tissue ablation via a single needle delivery system: initial experience with radiofrequency energy and ethanol. Prostate Cancer Prostatic Dis 2002; 5:183-188.
25. Plante MK, Marks LS, Anderson R, et al. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 2007; 177:1030-1035. This study was a phase I/II trial on 79 men with 6-month follow-up, assessing the safety and efficacy of transurethral ethanol ablation of the prostate (TEAP) as a treatment for men with symptomatic BPH. TEAP was shown to have widespread applicability and promise as a minimally invasive treatment option. This study was the first investigational new drug (IND) study for an injectable agent for the treatment of BPH.
26. Grise P, Plante M, Palmer J, et al. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): A European Multi-Center Evaluation. Eur Urol 2004; 46:496-502.
27. Larson BT, Netto N, Huidobro C, et al. Intraprostatic injection of alcohol gel for the treatment of benign prostatic hyperplasia: preliminary clinical results. ScientificWorldJournal 2006; 6:2474-2480.